New psoriasis pill shows promise in early trial
NCT ID NCT07204639
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This phase 2 study tests whether a new drug called RAP-103, taken as a pill once or twice daily for 8 weeks, can improve skin symptoms and quality of life in 90 adults aged 18-70 with moderate-to-severe psoriasis. Participants are randomly assigned to receive one of two doses of RAP-103 or a placebo. The study measures skin clearance and side effects, aiming to find a better treatment option for this chronic condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Innovacion y Desarrollo de Estrategias en Salud
Mexico City, Mexico City, 14320, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.